The CHMP has recommended a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) in adults with insufficiently controlled hypertension. The opinion arrives as the Institute for Clinical and Economic Review (ICER) has put a price benchmark on the drug that sits far below its US list price. Payers in Europe will meet a new product whose benefit over cheap generics ICER rates as unproven.
Where the drug stands
The CHMP opinion, dated 13 November 2026, awaits a European Commission decision, and the EMA page lists no conditions. In the US, the FDA approved Baxfendy in May 2026 as an add-on to other antihypertensives for adults whose blood pressure is not adequately controlled.
The pivotal BaxHTN trial (12 weeks, 796 patients) reported a placebo-adjusted fall in seated systolic blood pressure of 9.8 mmHg at 2 mg and 8.7 mmHg at 1 mg. The placebo group fell by 5.8 mmHg.
What ICER's benchmark says
ICER's revised evidence report, posted on 1 October 2026, sets a health-benefit price benchmark of $1,400 to $2,500 a year for baxdrostat. AstraZeneca's list price is $10,950 a year, and ICER says a discount of 78–87% would be needed to reach its range.
The benchmark follows from the ratings. ICER found baxdrostat "promising, but inconclusive" against spironolactone and eplerenone, and "comparable or inferior" against amlodipine. Its draft report added that open questions remain on long-term effects, patient-important outcomes and efficacy and safety in chronic kidney disease. AstraZeneca replied that Baxfendy offers "clinically meaningful blood pressure reductions supported by a robust body of scientific evidence".
ICER's process continues. Midwest CEPAC, ICER's advisory council, held its public meeting on 29 October 2026, and the final evidence report and meeting summary are listed for 30 November 2026.
The comparator problem in Europe
The ICER ratings show where European appraisals will press. The relevant comparators are older generic drugs (spironolactone, eplerenone and amlodipine), not other novel agents. A 9.8 mmHg placebo-adjusted reduction is clinically meaningful, but the comparison that decides cost-effectiveness is against established generic therapy, and ICER found that evidence inconclusive.
NICE is already part of the way through its appraisal. The single technology appraisal (ID6623) is in progress, and on 8 October 2026 NICE noted that it is rescheduling the committee discussion "to align with latest regulatory expectations", with an update to follow. The committee date is therefore open, and the CHMP opinion gives it a firmer regulatory anchor.
What it means for market access teams
- Build the evidence plan around generics. Network meta-analyses and indirect comparisons against spironolactone, eplerenone and amlodipine are the evidence that will carry the cost-effectiveness case. Placebo-controlled results alone will not.
- Plan for a visible US benchmark. ICER's range is public and will be cited in European price discussions. Teams with a US price in mind should model how a gap of this size reads to payers who reference it, and how it affects launch sequencing.
- Fill the outcome gaps early. ICER named long-term outcomes, patient-important endpoints and chronic kidney disease. Payers that see the same gaps will ask for managed entry or post-launch data collection.
- Watch the final report. The final evidence report on 30 November 2026 may move the benchmark, and the lorundrostat range of $760 to $1,600 shows how a second entrant would be priced against the same anchor.
We expect hypertension to become a test of how HTA bodies value a mechanistically new drug in a market full of cheap, effective generics. To discuss what that means for your evidence plan and pricing strategy, get in touch.